- Home
- IVT vs EWTX Comparison
IVT vs EWTX Comparison
Compare IVT & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IVT | EWTX |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.5B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | IVT | EWTX |
|---|---|---|
| Price | $28.49 | $25.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $32.20 | ★ $34.13 |
| AVG Volume (30 Days) | 567.1K | ★ 1.5M |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.33% | N/A |
| EPS Growth | ★ 1421.59 | N/A |
| EPS | ★ 1.51 | N/A |
| Revenue | ★ $293,020,000.00 | N/A |
| Revenue This Year | $9.77 | N/A |
| Revenue Next Year | $7.05 | N/A |
| P/E Ratio | $18.89 | ★ N/A |
| Revenue Growth | ★ 9.60 | N/A |
| 52 Week Low | $25.21 | $10.60 |
| 52 Week High | $31.04 | $32.61 |
Technical Indicators
Market Signals| Indicator | IVT | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.02 | 63.01 |
| Support Level | $28.61 | $20.14 |
| Resistance Level | $29.34 | $25.00 |
| Average True Range (ATR) | 0.49 | 1.64 |
| MACD | 0.01 | -0.28 |
| Stochastic Oscillator | 47.88 | 96.28 |
Price Performance
Historical ComparisonAbout IVT InvenTrust Properties Corp.
InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.